Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Reducing Disparities in Lupus and Lupus Nephritis Care

Drs Karen Costenbader and Brad Rovin discuss current disparities in lupus and lupus nephritis, including prevalence, social determinants of health, medication adherence, representation in clinical trials, and what healthcare professionals can do to address these disparities.
Karen H. Costenbader, MD, MPH
Brad H. Rovin, MD
Released: June 2, 2022

In this episode, Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, discuss health disparities in systemic lupus erythematosus and lupus nephritis. Topics include:

  • Disproportionate prevalence among marginalized groups in the United States
  • Lupus-related social determinants of health
  • Challenges with medication adherence
  • Strategies to reduce these disparities

Information on this Educational Activity


Karen H. Costenbader, MD, MPH

Professor of Medicine
Department of Medicine
Harvard Medical School
Director, Lupus Program
Division of Rheumatology, Inflammation and Immunity
Brigham and Women's Hospital
Boston, Massachusetts

Karen H. Costenbader, MD, MPH, has disclosed that she has received research funding from Exagen, Gilead Sciences, and Merck and consulting fees from Amgen, AstraZeneca, GlaxoSmithKline, Janssen, and Lilly.
Brad H. Rovin, MD

Professor and Director, Division of Nephrology
The Lee A. Hebert Professor of Nephrology
Medical Director
, The Ohio State Center for Clinical Research Management
The Ohio State University Wexner Medical Center
Columbus, Ohio

Brad H. Rovin, MD, has disclosed that he has received funds for research from Aurinia Pharmaceuticals, Biocryst, Biogen Idec, Bristol-Myers Squibb, Callidatis, Chemocentryx, Human Genome Sciences, Idorsia, and Lucin and consulting fees from Admirx, Alexion, AstraZeneca, Aurinia Pharmaceuticals, Biocryst, Biogen Idec, Bristol-Myers Squibb, Callidatis, Chugai Pharma, Corrona, EMD Serono, Genentech/Hoffman-La Roche, Janssen, Kezar Life Sciences, Lilly, Morphosys, Novartis, Omeros, Otsuka, Pfizer, Principia, and Travere Therapeutics.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This educational activity is supported by an educational grant from

Related Content

Experts review therapeutic interventions for NAFLD/NASH, from Clinical Care Options (CCO)

Manal F. Abdelmalek, MD, MPH
Program Director
Rohit Loomba, MD, MHSc Brent Tetri, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Physician Assistants: 1.5 AAPA Category 1 CME Credits Released: December 7, 2022 Expired: December 6, 2023

Learn about health disparities in anemia of CKD that affect patient outcomes and strategies to improve screening and management in these patient populations, from Clinical Care Options (CCO)

Santosh Saraf, MD Milda Saunders, MD, MPH Released: December 7, 2022

Get the latest evidence-based updates on systemic, targeted therapies for the management of moderate to severe atopic dermatitis for patients of all ages!

Robert Sidbury, MD, MPH Jonathan Silverberg, MD Released: December 6, 2022

Unlocked downloadable slides featuring an overview of the challenges of traditional anemia treatment in patients with CKD, from Clinical Care Options (CCO)

person default Ajay Singh, MBBS, FRCP, MBA Released: November 18, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings